Marchesini Group and AST have entered a strategic partnership that combines their expertise, technologies, and global reach.

ProBioGen and Spica Therapeutics, a biotechnology company advancing pathogenic macrophage subset-targeted immunotherapies, ...

Cellular Origins, a company that enables the manufacturing of cell therapies at scale, has completed a $40 million ...

Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma for the development, ...

Mirum Pharmaceuticals Inc. has agreed to acquire Bluejay Therapeutics, a privately held biotechnology company focused on ...

Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

Quotient Sciences and Intrepid Labs have announced a multi-year strategic partnership to advance the use of artificial ...

Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Daniel J. O'Connor as President & Chief ...

As 2026 approaches, the clinical research and development landscape is evolving beyond traditional scientific innovation with ...

Vetter, a globally leading CDMO, announced the retirement of its Managing Director, Thomas Otto, after over 35 years at the ...

Neurimmune has expanded its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, an AstraZeneca company ...

The FDA has approved BMS’ Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy, for adults with ...